View Older Stories View More Recent Stories
-
Form SC 13D DICE Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders
-
Hemab Appoints Mads Behrndt as Chief Financial Officer
-
PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September
-
DTx Pharma to Present at Upcoming Investor Conferences
-
Ivantis Announces Settlement of Glaukos Patent Litigation
-
Form SC 13D/A POINT Biopharma Global Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
-
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
-
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
-
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate
-
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
-
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
-
Asher Bio Closes $108 Million Series B Financing
-
ARS Pharmaceuticals Raises $55 Million in Series D Funding for Launch Preparations of Neffy™ (epinephrine nasal spray)
-
PepGen Announces New Additions to Leadership Team and Board of Directors
-
DiCE Molecules Announces $60 Million Series C-1 Financing
-
Form SC 13G Aerpio Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Form SC 13G Adverum Biotechnologies, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G EyePoint Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G RxSight, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Icosavax, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
-
Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies
-
Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital
-
Form SC 13G DA32 Life Science Tech Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Tenaya Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Cytek Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
PepGen Announces Closing of $112.5 Million Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases
-
T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies
-
T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies
-
Ultrasound Disruptor Exo Secures $220M in Series C Funding Round
-
Form SC 13G TScan Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Thriveworks Partners with Wellington Management
-
Form SC 13G ARYA Sciences Acquisitio Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
-
Novo Holdings co-leads Hemab's US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
-
AavantiBio and Aldevron Announce Strategic Partnership to Develop Next Generation Gene Therapies for Rare Genetic Diseases
-
Form SC 13G POINT Biopharma Global Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
-
Form SC 13D Acumen Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
